Parametric Portfolio Associates LLC cut its stake in bluebird bio, Inc. (NASDAQ:BLUE) by 1.1% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,491 shares of the biotechnology company’s stock after selling 252 shares during the period. Parametric Portfolio Associates LLC’s holdings in bluebird bio were worth $2,363,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Bank of Montreal Can boosted its stake in bluebird bio by 118.9% in the 2nd quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock worth $176,000 after purchasing an additional 911 shares in the last quarter. Turner Investments LLC acquired a new stake in bluebird bio in the 2nd quarter worth approximately $184,000. SG Americas Securities LLC boosted its stake in bluebird bio by 17.9% in the 2nd quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 295 shares in the last quarter. Affinity Investment Advisors LLC acquired a new stake in bluebird bio in the 2nd quarter worth approximately $246,000. Finally, Trexquant Investment LP acquired a new stake in bluebird bio in the 2nd quarter worth approximately $294,000.

bluebird bio, Inc. (NASDAQ BLUE) opened at $144.75 on Tuesday. bluebird bio, Inc. has a 1-year low of $41.25 and a 1-year high of $164.80.

bluebird bio (NASDAQ:BLUE) last posted its earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the consensus estimate of ($1.68) by ($0.05). bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The firm had revenue of $7.71 million for the quarter, compared to analysts’ expectations of $8.47 million. During the same period last year, the firm earned ($2.07) earnings per share. bluebird bio’s revenue for the quarter was up 397.4% compared to the same quarter last year. equities analysts expect that bluebird bio, Inc. will post -6.76 earnings per share for the current year.

A number of research firms recently commented on BLUE. Zacks Investment Research cut shares of bluebird bio from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. BidaskClub cut shares of bluebird bio from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. Jefferies Group LLC reiterated a “buy” rating and issued a $88.00 target price on shares of bluebird bio in a research note on Friday, August 11th. Morgan Stanley upgraded shares of bluebird bio from an “underweight” rating to an “equal weight” rating in a research note on Friday. Finally, Evercore ISI upgraded shares of bluebird bio from an “in-line” rating to an “outperform” rating and set a $102.00 target price for the company in a research note on Monday, October 16th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and fourteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $131.05.

ILLEGAL ACTIVITY NOTICE: This piece was first published by Watch List News and is the property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.watchlistnews.com/bluebird-bio-inc-blue-position-reduced-by-parametric-portfolio-associates-llc/1684675.html.

In related news, insider Jeffrey T. Walsh sold 35,000 shares of bluebird bio stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $151.38, for a total value of $5,298,300.00. Following the sale, the insider now owns 62,305 shares of the company’s stock, valued at approximately $9,431,730.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Nick Leschly sold 25,667 shares of bluebird bio stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $115.18, for a total transaction of $2,956,325.06. Following the completion of the sale, the insider now directly owns 339,368 shares in the company, valued at approximately $39,088,406.24. The disclosure for this sale can be found here. Insiders sold a total of 185,518 shares of company stock worth $24,292,373 in the last three months. 3.90% of the stock is owned by corporate insiders.

bluebird bio Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.